XCUR
Exicure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.25
+1.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +34.6%
- EBIT
- +24.9%
- EPS
- -4.0%
- Free cash flow
- -16.2%
- Operating cash flow
- -29.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +42.2%
- EBIT
- +17.3%
- Net income
- +49.0%
- EPS
- +50.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026